Stock Ratings / Health Care / IRWD / dividends

CRMD (62) CLYM (29) NVCT (37) GERN (29) ⌘ Pro Terminal →

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.50 -3.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.47

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $598.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IRWD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IRWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ: IRWD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $3.50 (-3.31% 1D, market cap $598.2M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, IRWD ranks #153 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IRWD compare to CRMD and CLYM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IRWD carries a Roarable C (63/100 RQD), trailing P/E of 24.9x, gross margin of —, and ROIC of 85.0%. By comparison, CRMD (CorMedix Inc.) holds a C grade (62/100 RQD, P/E 3.7x, ROIC 45.5%, cap $595.5M) and CLYM (Climb Bio Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IRWD?

▼

Per IRWD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001446847), Ironwood Pharmaceuticals Inc. (Class A) generated $296.2M in revenue (-15.7% YoY), $24.0M in net income, and $127.0M in free cash flow against $396.9M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.47 (-0.79%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 42.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IRWD)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY IRWD SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 42.9% FCF Margin ($127.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$3.76-5.3% Next Q

Q2 (-2Q)

Grade B-$3.56-1.7% Next Q

Q3 (-1Q)

Grade B-$3.50+0% Next Q

Current

Grade C$3.50+0.9% Hist 90D α

Trajectory: B (71) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IRWD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, IRWD faces multiple-compression risk if 24.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.94) or 200D SMA ($3.98) invalidates the momentum regime and cuts Target Base ($3.58) toward Bear Floor ($2.79).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IRWD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IRWD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in IRWD & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on IRWD and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IRWD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.75%🛡️ HOLDING TREND SUPPORT

2026-11-02O $3.61H $3.62L $3.50C $3.50VOL 1.37M

RES: $4.61SUP: $3.36SMA50: $3.94SMA200: $3.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IRWD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IRWD Butterfly Map → + Track IRWD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.6%/yr Implied 5Y Growth

vs. -15.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IRWD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IRWD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IRWD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IRWD)

Health Care Rank #153 of 1016 ⚔️ CRMD vs IRWD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IRWD vs. CRMD, CLYM, NVCT, GERN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ironwood Pharmaceuticals Inc. (Class A) (IRWD) ranks #153 by composite RQD confidence (63/100, grade C) and #420 by equity capitalization ($598.2M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IRWD ACTIVE Ironwood Pharmaceuticals Inc. (Class A)	C	63/100	24.9x	—	85.0%	-3.31%	$598.2M	Benchmark Subject
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-25.46%	$595.5M	/crmd-vs-irwd →
CLYM Climb Bio Inc.	E	29/100	—	—	-35.0%	-0.77%	$593.3M	/clym-vs-irwd →
NVCT Nuvectis Pharma Inc.	D-	37/100	—	—	-35.0%	-0.48%	$605.6M	/nvct-vs-irwd →
GERN Geron Corporation	E	29/100	—	—	-20.2%	-5.47%	$607.9M	/gern-vs-irwd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001446847

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ironwood Pharmaceuticals Inc. (Class A) (IRWD) reported GAAP revenue of $296.2M (-15.7% vs. FY2024 revenue of $351.4M , and -33.1% cumulative change since FY2023) , GAAP net income of $24.0M, operating cash flow of $127.0M, and free cash flow of $127.0M (+22.8% YoY). On the balance sheet, IRWD closed FY2025 with $396.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$296.2M	$24.0M	$127.0M	$127.0M	$396.9M	—
FY2024 (FY)	2024-12-31	$351.4M	$880.0K	$103.5M	$103.4M	$350.9M	—
FY2023 (FY)	2023-12-31	$442.7M	-$1.03B	$183.4M	$183.4M	—	—

3. IRWD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IRWD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IRWD compare to CRMD and CLYM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IRWD?

Where is IRWD trading relative to its 50-day, 200-day, and 52-week technical levels?

IRWD last traded at $3.50 (-3.31% on volume of 1,470,631 shares), positioning the stock -11.17% below its 50-day simple moving average ($3.94) and -12.06% below its 200-day simple moving average ($3.98). Across its 52-week range of $1.61 to $5.78, IRWD sits at the 45.3% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($3.16 to $3.84).

IRWD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does IRWD pay a dividend and is it safe?

Ironwood Pharmaceuticals Inc. (Class A) (IRWD) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: IRWD RQD Cockpit IRWD 12M Forecast IRWD Earnings & Move IRWD Dividends & DRIP IRWD Insiders & 13F IRWD Whale Options IRWD Profit Sankey IRWD News & Why